Skip to main content
Top

Breast Cancer Research and Treatment

Issue 3/2014

Content (24 Articles)

Review

Breast edema in breast cancer patients following breast-conserving surgery and radiotherapy: a systematic review

Hanne Verbelen, Nick Gebruers, Tinne Beyers, Anne-Caroline De Monie, Wiebren Tjalma

Preclinical Study

AR collaborates with ERα in aromatase inhibitor-resistant breast cancer

Yassine Rechoum, Daniela Rovito, Domenico Iacopetta, Ines Barone, Sebastiano Andò, Nancy L. Weigel, Bert W. O’Malley, Powel H. Brown, Suzanne A. W. Fuqua

Preclinical study

JMJD2A-dependent silencing of Sp1 in advanced breast cancer promotes metastasis by downregulation of DIRAS3

Liliang Li, Pan Gao, Yuhua Li, Yiwen Shen, Jianhui Xie, Daming Sun, Aimin Xue, Ziqin Zhao, Zude Xu, Mingchang Zhang, Beixu Li, Jieqing Jiang

Preclinical study

An improved syngeneic orthotopic murine model of human breast cancer progression

Omar M. Rashid, Masayuki Nagahashi, Suburamaniam Ramachandran, Catherine Dumur, Julia Schaum, Akimitsu Yamada, Krista P. Terracina, Sheldon Milstien, Sarah Spiegel, Kazuaki Takabe

Preclinical study

Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer

M. Tanioka, K. Sakai, T. Sudo, T. Sakuma, K. Kajimoto, K. Hirokaga, S. Takao, S. Negoro, H. Minami, K. Nakagawa, K. Nishio

Preclinical Study

Identification and translational validation of novel mammaglobin-A CD8 T cell epitopes

S. D. Soysal, S. Muenst, J. Kan-Mitchell, E. Huarte, X. Zhang, I. Wilkinson-Ryan, T. Fleming, V. Tiriveedhi, T. Mohanakumar, L. Li, J. Herndon, D. Oertli, S. P. Goedegebuure, W. E. Gillanders

Preclinical study

Dichloroacetate enhances apoptotic cell death via oxidative damage and attenuates lactate production in metformin-treated breast cancer cells

Allison B. Haugrud, Yongxian Zhuang, Joseph D. Coppock, W. Keith Miskimins

Clinical trial

Impact of genetic variability and treatment-related factors on outcome in early breast cancer patients receiving (neo-) adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide, and docetaxel

C. Vulsteke, A. M. Pfeil, M. Schwenkglenks, R. Pettengell, T. D. Szucs, D. Lambrechts, M. Peeters, P. van Dam, A. S. Dieudonné, S. Hatse, P. Neven, R. Paridaens, H. Wildiers

Open Access Clinical trial

High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer

Martin P. Nilsson, Linda Hartman, Ulf Kristoffersson, Oskar T. Johannsson, Åke Borg, Karin Henriksson, Elsa Lanke, Håkan Olsson, Niklas Loman

Clinical trial

A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer

Gayle S. Jameson, Emanuel F. Petricoin, Jasgit Sachdev, Lance A. Liotta, David M. Loesch, Stephen P. Anthony, Manpreet K. Chadha, Julia D. Wulfkuhle, Rosa I. Gallagher, Kimberley A. Reeder, Mariaelena Pierobon, Monica R. Fulk, Nina A. Cantafio, Bryant Dunetz, William D. Mikrut, Daniel D. Von Hoff, Nicholas J. Robert

Clinical trial

Diagnostic accuracy of tactile imaging in selecting patients with palpable breast abnormalities: a prospective comparative study

Marios-Konstantinos Tasoulis, Konstantinos E. Zacharioudakis, Nikitas G. Dimopoulos, Dimitri J. Hadjiminas

Open Access Clinical trial

Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study

Patrizia Vici, Laura Pizzuti, Clara Natoli, Luca Moscetti, Lucia Mentuccia, Angela Vaccaro, Domenico Sergi, Luigi Di Lauro, Patrizia Trenta, Patrizia Seminara, Daniele Santini, Laura Iezzi, Nicola Tinari, Ilaria Bertolini, Valentina Sini, Marcella Mottolese, Diana Giannarelli, Francesco Giotta, Marcello Maugeri-Saccà, Maddalena Barba, Paolo Marchetti, Andrea Michelotti, Isabella Sperduti, Teresa Gamucci

Epidemiology

Trends in 5-year survival rates among breast cancer patients by hormone receptor status and stage

Lu Chen, Hannah M. Linden, Benjamin O. Anderson, Christopher I. Li

Epidemiology

Breast cancer in young women: have the prognostic implications of breast cancer subtypes changed over time?

Wilson Sheridan, Tyldesley Scott, Speers Caroline, Zheng Yvonne, Bernstein Vanessa, Voduc David, Gelmon Karen, Chia Stephen

Epidemiology

Association of H3K9me3 and H3K27me3 repressive histone marks with breast cancer subtypes in the Nurses’ Health Study

Megan A. Healey, Rong Hu, Andrew H. Beck, Laura C. Collins, Stuart J. Schnitt, Rulla M. Tamimi, Aditi Hazra

Epidemiology

Genome-wide DNA methylation profiling reveals parity-associated hypermethylation of FOXA1

Sagar Ghosh, Fei Gu, Chou-Miin Wang, Chun-Lin Lin, Joseph Liu, Howard Wang, Peter Ravdin, Yanfen Hu, Tim H. M. Huang, Rong Li

Brief Report

Mesothelin expression is associated with poor outcomes in breast cancer

Yun R. Li, Rena R. Xian, Amy Ziober, Jose Conejo-Garcia, Alfredo Perales-Puchalt, Carl H. June, Paul J. Zhang, Julia Tchou

Rebuttal Letter

Response to Santoro et al

D. Gareth Evans

Erratum

Erratum to: MRI breast screening in high-risk women: cancer detection and survival analysis

D. Gareth Evans, Nisha Kesavan, Yit Lim, Soujanye Gadde, Emma Hurley, Nathalie J. Massat, Anthony J. Maxwell, Sarah Ingham, Rosalind Eeles, Martin O. Leach, Anthony Howell, Stephen W. Duffy

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine